SAN LUIS OBISPO, California – April 4, 2000 – FzioMed, Inc. announced today that the U.S. Patent and Trademark Office has issued two additional patents to the Company. Both patents are related to Oxiplex™, a unique polymer technology developed by FzioMed to produce bioresorbable materials for a variety of medical applications.
FzioMed is developing a diverse line of Oxiplex™ products targeting medical markets such as post-surgical adhesion prevention, osteoarthritis and drug delivery. Ron Haynes, FzioMed President and CEO, said, “These new patents further broaden FzioMed’s proprietary position in the field of adhesion prevention. We are building a strong competitive position for the future Oxiplex™ product line.” Post-surgical adhesions are abnormal, fibrous attachments between tissues and organs that can form in the body following surgery. Adhesions tether organs and tissues together and can cause major complications such as chronic pain, infertility and intestinal obstruction.
Founded in 1996, FzioMed is a medical company engaged in the development and manufacture of bioresorbable materials based on the Company’s proprietary Oxiplex™ technology. Oxiplex™ is a unique polymer technology that can be formulated for a variety of targeted uses. Clinical trials of FzioMed’s first product, a bioresorbable Oxiplex™ Film for adhesion prevention in laparoscopic and open surgery, are underway in the United States. Two additional products, both bioresorbable gels, are in late-stage pre-clinical development for adhesion prevention in spine and pelvic/gynecology surgeries. FzioMed has developed the FilmSert™ instrument, a tool designed to deliver Oxiplex™ film products in a laparoscopic surgical procedure. The Company is also developing Oxiplex™ formulations for future targets including osteoarthritis.
Oxiplex™ and FilmSert™ are registered trademarks of FzioMed, Inc.